Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ICP-332 in Healthy Subjects
NCT05399030Phase 1Completed
- Sponsor
- InnoCare Pharma
- Start
- Aug 2021
- Primary completion
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in atopic dermatitis (AD) comparing ICP-332 with Placebo (2 arms). Primary endpoint: Number of participants with Treatment-Emergent Adverse Events. Started Aug 2021; status: completed.
02
Drugs
soficitinib
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT05399030.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05399030.